TB and interstitial lung disease: a systematic review and meta-analysis

INTRODUCTION To determine the frequency of TB among patients with interstitial lung diseases (ILDs). METHODS We performed a comprehensive search in the PubMed/Medline, EMBASE and Scopus databases up to 1 August 2023 of studies reporting on the prevalence of TB among patients with ILDs. RESULTS Twelv...

Full description

Saved in:
Bibliographic Details
Published in:The international journal of tuberculosis and lung disease Vol. 28; no. 3; pp. 130 - 135
Main Authors: Rezaee, M., Azizi, N., Danaei, B., Davari, A., Nejadghaderi, S. A., Sarmastzadeh, T., Rahmannia, M., Khalili, F., Shahidi-Bonjar, A. H., Centis, R., D'Ambrosio, L., Sotgiu, G., Migliori, G. B., Nasiri, M. J.
Format: Journal Article
Language:English
Published: France International Union Against Tuberculosis and Lung Disease 01-03-2024
International Union against Tuberculosis and Lung Disease (IUATLD)
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:INTRODUCTION To determine the frequency of TB among patients with interstitial lung diseases (ILDs). METHODS We performed a comprehensive search in the PubMed/Medline, EMBASE and Scopus databases up to 1 August 2023 of studies reporting on the prevalence of TB among patients with ILDs. RESULTS Twelve studies comprising 3,817 patients with ILD were found: the pooled prevalence of TB among ILD patients was 11.0% (95% CI 5.4-21.0). In the subgroup analysis, the TB rate among patients with silicosis and idiopathic pulmonary fibrosis (IPF) was respectively 35.6% (95% CI 32.6-38.8) and 4.4% (95% CI 3.6-5.3) (P = 0.00). The frequency of TB among ILD patients was higher in high TB burden countries than in low/intermediate-burden countries: 26.3%, 95% CI 17.7-37.3 vs. 4.9%, 95% CI 3.3-7.2; P = 0.00. CONCLUSIONS This study shows the frequency of TB among ILD patients. The meta-analysis reveals a significantly increased prevalence of TB among ILD patients with silicosis compared to IPF, and among individuals in high TB burden countries than in those with low/intermediate burden. The study results can help physicians and policymakers make efficient decisions for prompt screening and anti-TB treatment initiation in ILD patients.
Bibliography:(R) Medicine - General
1027-3719(20240301)28:3L.130;1-
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:1027-3719
1815-7920
DOI:10.5588/ijtld.23.0428